Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

被引：0

作者：

Hauser, Stephen ^{[1
]}

Li, David ^{[2
]}

Calabresi, Peter ^{[3
]}

O'Connor, Paul ^{[4
]}

Bar-Or, Amit ^{[5
,6
]}

Barkhof, Frederik ^{[7
]}

Sauter, Annette ^{[8
]}

Leppert, David ^{[9
]}

Masterman, Donna ^{[8
]}

Tinbergen, Jeroen ^{[8
]}

Kappos, Ludwig ^{[10
,11
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] Univ Toronto, Dept Neurol, Toronto, ON, Canada

[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada

[6] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada

[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands

[8] F Hoffmann La Roche Ltd, Basel, Switzerland

[9] PDCN F Hoffmann La Roche, Basel, Switzerland

[10] Univ Basel Hosp, CH-4031 Basel, Switzerland

[11] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S31004

引用

页数：2

共 50 条

[41] Natural interferon beta in the treatment of relapsing-remitting multiple sclerosis:: A multicenter, randomized, MRI-based, phase II clinical trial
Fernández, O
Antigüedad, A
Arbizu, T
Burgués, S
Capdevila, A
de Castro, P
de Sá, JCC
García-Merino, JA
Izquierdo, G
Magalhaes, A
Montalbán, X
Zarranz, JJ
REVISTA DE NEUROLOGIA, 1999, 29 (12) : 1093 - 1099
[42] Safety and efficacy of rituximab in adults with relapsing-remitting multiple sclerosis: results of a phase II placebo-controlled, multicentre trial through 48 weeks
Waubant, E.
Hauser, S.
Amold, D. L.
Vollmer, T.
Antel, J. P.
Fox, R.
Bar-Or, A.
Panzara, M.
Sarkar, N.
Agarwal, S.
Langer-Gould, A.
Smith, C.
MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165
[43] Monitoring cognition in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients
White, J.
Gabriele, S.
Lin, D.
Vindici, J.
Teoh, S.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 214 - 214
[44] Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
Panitch, H
Francis, G
ANNALS OF NEUROLOGY, 1997, 42 (03) : T262 - T262
[45] MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
Francis, G
Evans, A
Panitch, H
ANNALS OF NEUROLOGY, 1997, 42 (03) : T289 - T289
[46] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
Rodriguez de Castro, Belen
Martinez-Mugica Barbosa, Cristina
Ayastuy Ruiz, Aitor
Fernandez Gonzalez, Beatriz
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
[47] Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial
Hemmer, Bernhard
Wiendl, Heinz
Roth, Karsten
Wessels, Hendrik
Hoefler, Josef
Hornuss, Cyrill
Liedert, Bernd
Selmaj, Krzysztof
JAMA NEUROLOGY, 2023, 80 (03) : 298 - 307
[48] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
Putzki, Norman
Kiriaki, Kollia
Katsarava, Zaza
Woods, Sophia
Give, Ezinne
Diener, H.
NEUROLOGY, 2008, 70 (11) : A90 - A90
[49] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
Oh, Jiwon
O'Connor, Paul W.
CNS DRUGS, 2013, 27 (08) : 591 - 609
[50] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
Jiwon Oh
Paul W. O’Connor
CNS Drugs, 2013, 27 : 591 - 609

← 1 2 3 4 5 →